Anaplastic lymphoma kinase (ALK)- positive tumors

Clinical trials for Anaplastic lymphoma kinase (ALK)- positive tumors explained in plain language.

Never miss a new study

Get alerted when new Anaplastic lymphoma kinase (ALK)- positive tumors trials appear

Sign up with your email to follow new studies for Anaplastic lymphoma kinase (ALK)- positive tumors, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

Last-Resort access to ceritinib for ALK-Positive cancer patients

Disease control Expanded access (ended)

This program provides access to the drug ceritinib (LDK378) for patients with serious ALK-positive tumors, including non-small cell lung cancer, who have no other treatment options and cannot join a clinical trial. It is designed for individual patients whose doctors request the …

Matched conditions: ANAPLASTIC LYMPHOMA KINASE (ALK)- POSITIVE TUMORS

Sponsor: Novartis Pharmaceuticals • Aim: Disease control

Last updated Jun 27, 2026 12:01 UTC

Anaplastic lymphoma kinase (ALK)- positive tumors

Get alerted when new Anaplastic lymphoma kinase (ALK)- positive tumors trials appear

Last-Resort access to ceritinib for ALK-Positive cancer patients